MiniMed Group is trading at $23.84 (+4.75%) in pre-market after strong fiscal Q1 results, raised revenue guidance, and recent analyst price-target increases.
- No fresh September 10, 2026 company-specific catalyst was identified.
- A September 10 investor presentation is scheduled, but available sources do not explicitly link it to the pre-market gain.
- Broader healthcare weakness makes sector momentum an unlikely explanation.